Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug
Source: Bse
Suven Life Sciences Limited (SUVEN)
Small CapPharma stocks · Small cap · NSE
Suven Life Sciences Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result06 Aug, 06:17 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
66BullishSMA20 -15.0% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 44
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
SUVEND candles · FIT view+43.6%Latest close ₹290.05 on 2026-10-19
Bar
-4.6%
RSI
37
MACD hist
-0.33
52W pos
59%
2026-10-19O ₹303.95H ₹304.35L ₹288.40C ₹290.05Vol 3.5L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
SUVENNifty PharmaNifty 500
- SUVEN
- -14.3%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -8.7 pp
Chart stats
19 Oct 2026- From 52W high
- -28.1%
- 52W range position
- 59%
- ATR (14)
- 5.3%
- Volume vs 20D
- 0.55x
- Avg traded value
- ₹19.7 Cr
- 20D price channel
- ₹276.5 - ₹345.2
₹403.4
₹124.1 - ₹403.4
₹15.4
Latest completed session
20-session average
39.6% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · OVERVALUED29
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average32
Revenue +100.0% · PAT NDF YoY
Technical
Bullish66
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence61
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 32/100margin compression · Rev +100% YoY · +100% QoQ
Filed 06 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹4 Cr | +100.0% | +100.0% |
| EBITDA | ₹-132 Cr | -158.8% | -158.8% |
| Operating margin | -3711.0% | -99700 bps | -38000 bps |
| PAT | ₹-128 Cr | NDF | NDF |
| PAT margin | -3200.0% | -60000 bps | -90000 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 13.66
- EV/EBITDA
- —
- Market Cap
- 8655.00Cr
Profitability
- ROE
- -81.50%
- ROCE
- -79.50%
- ROA
- -56.41%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- -12.00%
- EPS 5Y
- 23.00%
- Revenue 3Y
- -19.00%
- EPS 3Y
- 62.00%
Balance Sheet
- Debt/Equity
- 0.03
- Interest Coverage
- -366.00×
- Altman Z
- 5.97
- Book Value
- 22.40
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 4/5
- OCF
- -300.00 Cr
- EPS TTM
- -14.44
Shareholding
- Promoter Hold
- 65.47%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 65%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 7.0+0.0% vs prev
Net Profit
₹ CrLatest: -276-71.4% vs prev
Return on Equity
%Latest: -46.7+68.1% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term uptrend intact. RSI 37. Wait for confirmation.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~17.6% over last month) — short-term momentum negative.
- RSI(14) at 37 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 28% off 52W high · 134% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
85
RS percentile
Stage 2 UptrendEstablished S2
1M return
-15.1%
3M return
-14.3%
6M return
+36.4%
1Y return
+49.5%
RS 1D
-2
RS 20D
-9
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 4.4% above the 30-week proxy.
- The 50-DMA is above the 30-week proxy and its slope is rising +8.8%.
50-DMA
price below
200-DMA
price above
S2 entered
18 May 2026
S2 age
109 trading sessions
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 142.97-3.46%
RS vs Nifty 500143
Valuation & peers
U-Score 29 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 29 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation2/30
Growth14/25
Quality0/20
Balance Sheet9/15
Cash Flow3/10
Piotroski
3/9 (+1)
Penalties
0
Raw sum
29
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
29/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 9/15 to the score.
- Growth contributes 14/25 to the score.
- Cash flow contributes 3/10 to the score.
Main drags
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Cash flow is weaker at 3/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
13.7
EV/EBITDA
—
ROE
-81.5%
ROCE
-79.5%
FCF Yield
—
Debt/Equity
0.0
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
29
Previous: 29
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
29
29
29
29
29
29
29
29
29
29
29
29
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
45.0
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MOREPENLAB
Small
Morepen Laboratories Limited
Healthcare Services
match 166
20
63.1
5.3%
-1007%
OVERVALUED
SANOFICONR
Small
Sanofi Consumer Healthcare India Limited
Healthcare Services
match 165
64
32.5
71.6%
+33%
UNDERVALUED
SENORES
Small
Senores Pharmaceuticals Limited
Healthcare Services
match 165
35
48.2
13.4%
-2%
WATCHLIST
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 164
33
320.0
1.5%
-846%
WATCHLIST
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 164
46
113.0
22.2%
-146%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Suven Life Sciences Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
61Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 32nd percentile of the scored universe and 22nd percentile within Pharma. Main check: financial discipline is weak at 30/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
66 docs text-extracted · 14 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
32nd percentile
overall median 67 · Pharma: 22nd pctile, median 70 · Small: 36th pctile, median 66
Evidence depth
Financial-only
66 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
52
watch · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
30
weak · capital discipline
Results
57
watch · quarterly consistency
Trust positives
- ▸Promoter holding is 65.5%.
- ▸Promoter pledge is zero.
- ▸4 years of positive FCF.
- ▸Debt/equity is 0.03.
Trust risks
- ▸Operating cash flow is negative at ₹-300 Cr.
- ▸Promoter holding fell 1.9%.
- ▸ROCE is low at -79.5%.
- ▸ROE is low at -81.5%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Suven Life Sciences Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 31 Jul - Newspaper Adv. regarding Notice of 37th Annual General Meeting of the Company and E-voting information
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Jul - Special window for Re-Lodgment of transfer requests of Physical shares
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.